CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

Blood Cancer J. 2017 Dec 20;7(12):659. doi: 10.1038/s41408-017-0023-x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Bispecific / therapeutic use*
  • Antigens, CD19 / immunology
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / immunology*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / pathology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology*

Substances

  • Antibodies, Bispecific
  • Antigens, CD19
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • blinatumomab